Abstract: The present invention relates to a sulphated heteropolymer polysaccharide obtainable from the order of Prasinococcales polysaccharide wherein the average molecular weight of the polysaccharide is between 1,000 and 40,000 kDa, or a fragment of for use in the treatment of skin irritation, wound repair, fibrotic conditions, keloid trait scarring or keloid scars, viral infection, as a biological carrier or scaffold or bio-lubricant; methods of preparing the same and uses thereof, such as in antiviral compositions.

Abstract: A process for the isolation of modified polysaccharide product from potato, in particular a polysaccharide product that can be used as an immunomodulatory is described. More particularly, the extraction and modification of a rhamnogalacturonan I(RG-1) fragment product from a potato using a defined process, and the use of this product to provide immunomodulatory activity to a subject.

Abstract: There is provided a composition comprising a polysaccharide obtainable from the microalgae, Prasinococcus capsulatus and strains related to P. capsulatus for use in the treatment of disorders of the immune system, for example in psoriasis and dermatological conditions, internal immune system disorders, in particular gut inflammatory conditions and respiratory conditions. Further, there is provided derivatives of a polysaccharide obtainable from the microalgae, Prasinococcus capsulatus or an algal strain related to P. capsulatus and the use of such derivatives in the treatment of disorders of the immune system.

Abstract: A process for the isolation of modified polysaccharide product from potato, in particular a polysaccharide product that can be used as an immunomodulatory is described. More particularly, the extraction and modification of a rhamnogalacturonan I(RG-1) fragment product from a potato using a defined process, and the use of this product to provide immunomodulatory activity to a subject.

Abstract: There is provided a composition comprising a polysaccharide obtainable from the microalgae, Prasinococcus capsulatus and strains related to P. capsulatus for use in the treatment of disorders of the immune system, for example in psoriasis and dermatological conditions, internal immune system disorders, in particular gut inflammatory conditions and respiratory conditions. Further, there is provided derivatives of a polysaccharide obtainable from the microalgae, Prasinococcus capsulatus or an algal strain related to P. capsulatus and the use of such derivatives in the treatment of disorders of the immune system.

Abstract: There is provided a composition comprising a polysaccharide obtainable from the microalgae, Prasinococcus capsulatus and strains related to P. capsulatus for use prophylactically and/or therapeutically in the treatment of disorders of the immune system, for example in psoriasis and dermatological conditions, internal immune system disorders, in particular gut inflammatory conditions and respiratory conditions. Further, there is provided derivatives of a polysaccharide obtainable from the microalgae, Prasinococcus capsulatus or an algal strain related to P. capsulatus and the use of such derivatives prophylactically and/or therapeutically in the treatment of disorders of the immune system.

Abstract: There is provided a composition comprising a polysaccharide obtainable from the microalgae, Prasinococcus capsulatus and strains related to P. capsulatus for use prophylactically and/or therapeutically in the treatment of disorders of the immune system, for example in psoriasis and dermatological conditions, internal immune system disorders, in particular gut inflammatory conditions and respiratory conditions. Further, there is provided derivatives of a polysaccharide obtainable from the microalgae, Prasinococcus capsulatus or an algal strain related to P. capsulatus and the use of such derivatives prophylactically and/or therapeutically in the treatment of disorders of the immune system.

Abstract: rDNA corresponding to an endosymbiotic bacteria associated with Ecteinascidia turbinata has been identified. The bacterium appears to be responsible for the biosynthesis of ecteinascidin compounds. The 16S rDNA sequence corresponding to Candidatus Endoecteinascidia frumentensis SEQ ID NO: 1 has been deposited in GeneBank with the accession number AY054370.